Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Slides:



Advertisements
Similar presentations
Lecture outline Signals for T cell activation
Advertisements

Pathogen invasion MM Neutrophil DC PRR Naïve T cell CTL IFN-  B cell IgG IL-4, IL-5, IL-6 Th1 Th2 IgE IgA Cell lysis Tr cell IL-1 , TNF- , chemokines.
T cell-mediated immunity Chapter 8
Signals for T cell activation Costimulation and the B7:CD28 family
World Congress on Breast Cancer, Birmingham, August 4 th 2015 Radio-immunotherapy of cancer Therapeutic efficacy, underlying mechanisms and potential applications.
Immunology molecular medicine 3 Conleth Feighery.
Activation of T Lymphocytes
M1 – Immunology CYTOKINES AND CHEMOKINES March 26, 2009 Ronald B
M1 – Immunology EFFECTOR T CELL FUNCTIONS (Part I) March 27, 2009 Ronald B. Smeltz, Ph.D. Microbiology and Immunology
David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J
Cellular Immune response
Chapter 4 T Cell Mediated Immune Response(CMI)
Tumor Immunity: Exploring the Role of a Checkpoint
Avoiding Immune Detection
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Immunological Tolerance
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Radiation-induced effects on tumour cells
Tumor Immunology Ali Al Khader, MD Faculty of Medicine
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Converting Cold into Hot Tumors by Combining Immunotherapies
Figure 1 Four nodes to target when inducing anti-tumour immunity
Cancer Immunotherapy by Dendritic Cells
Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.
Oncology Meets Immunology: The Cancer-Immunity Cycle
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.
by Edward S. Morris, Kelli P. A. MacDonald, and Geoffrey R. Hill
Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD 
David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J
Colorectal cancer vaccines: Principles, results, and perspectives
Mark A. Schroeder, Jaebok Choi, Karl Staser, John F. DiPersio 
Stefan H.E. Kaufmann, Shreemanta K. Parida  Cell Host & Microbe 
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
Figure 1 The role of CTLA4 and PD1 in T cell activation
Low-dose cyclophosphamide (Cy) reduces intratumoral Treg numbers and promotes enhanced T-cell trafficking and activation within the tertiary lymphoid aggregates.
Figure 2 Site of action of checkpoint inhibitors and agonists being
Robert J Korst, MD, Ronald G Crystal, MD 
Mechanisms of immune escape in the tumor microenvironment.
Mechanism of CTLA-4-induced immunosuppression.
Nat. Rev. Endocrinol. doi: /nrendo
The Tim-3 pathway in cancer.
Schematic representation of mechanisms leading to the synergy of anti-CD137 and anti–PD-1 immunostimulatory mAbs. Schematic representation of mechanisms.
Turning Tumors into Vaccines: Co-opting the Innate Immune System
Figure 1 Mechanisms of action of immunotherapy modalities
Tumor-Associated Macrophages: From Mechanisms to Therapy
Immunotherapy for Lung Cancer
Nat. Rev. Urol. doi: /nrurol
Immunology Dr. Refif S. Al-Shawk
Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies  Samuel T Workenhe, Karen L Mossman 
Stefan H.E. Kaufmann, Shreemanta K. Parida  Cell Host & Microbe 
Deciphering and Reversing Tumor Immune Suppression
Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies  Samuel T Workenhe, Karen L Mossman 
Tumor Immunology Ali Al Khader, MD Faculty of Medicine
Cell-mediated immunity Regulation of the immune response
Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;
Vaccines for Lung Cancer
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.
Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)
CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell.
Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.
Anti–PD-1/PD-L1–mediated acquired resistance is dependent on CD38-generated adenosine in the tumor microenvironment. Anti–PD-1/PD-L1–mediated acquired.
IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.
Cartoon of OV-mediated effects in tumor.
Stable IL-10: A New Therapeutic that Promotes Tumor Immunity
Fig. 1 Schematic of doxorubicin-loaded sHDL (sHDL-DOX) for chemo-immunotherapy. Schematic of doxorubicin-loaded sHDL (sHDL-DOX) for chemo-immunotherapy.
Presentation transcript:

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Radiation induces DNA damage and tumor cell death by promoting tumor cell expression of Fas and MHC class I; dying tumor cells release ATP, tumor antigens, and danger signals such as HMGB1 and calreticulin. Radiation also increases tumor cell expression of PD-L1, secretion of TGFβ, and suppression of CD4+ Tregs. Tumor antigens captured by antigen-presenting cells (APC) are processed and presented on MHC class I molecules in the draining lymph node to tumor antigen–specific T cells in conjunction with costimulation to promote activation and proliferation. CTLA-4 can bind B7-1 to downregulate T-cell activation. Activated CTLs leave the lymph node, follow inflammatory chemokines, and migrate to tumor sites. PD-L1 and PD-1 can interact to suppress CTL activation; various α-CTLA-4, α-PD-L1, and α-PD-1 mAbs have been developed and used successfully in cancer immunotherapies. CTL antitumor activity includes secretion of IFNγ and TNF, suppression of MDSCs, expression of perforin and granzyme, and activation of Fas ligand–mediated tumor cell apoptosis. Chad Tang et al. Cancer Immunol Res 2014;2:831-838 ©2014 by American Association for Cancer Research